Respiratory Medicine Case Reports (Jan 2023)

A case of severe thrombocytopenia after the first exposure to rifampicin

  • Chinatsu Nakane,
  • Koji Nishimoto,
  • Ei Kishimoto,
  • Kosuke Suzuki,
  • Emiko Nakagawa,
  • Moeko Morikawa,
  • Yurina Murakami,
  • Yoichiro Aoshima,
  • Sayomi Matsushima,
  • Masanori Harada,
  • Tomohiro Uto,
  • Shiro Imokawa

Journal volume & issue
Vol. 42
p. 101823

Abstract

Read online

Severe immune thrombocytopenia is a rare side-effect of rifampicin (RFP) and can be life-threatening. Here, we report the case of a 74-year-old male with tuberculous pleurisy who developed severe thrombocytopenia after first exposure to RFP. Platelet count decreased to 1 × 103/μL after 7 days of treatment with RFP, isoniazid, ethambutol, and pyrazinamide. After all the drugs were discontinued, the platelet count recovered. As thrombocytopenia did not occur after re-administration of drugs other than RFP, the patient was diagnosed with RFP-induced thrombocytopenia. Clinicians should be aware that RFP can induce acute and severe thrombocytopenia even without previous exposure to this drug.

Keywords